PITTSBURGH -- (BUSINESS WIRE) -- RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, presented results of a multi-institutional prospective study from 492 patient outcomes on integrated molecular pathology (IMP) at the recently held 2013 ACG Annual Meeting in San Diego, CA. Final data results validate the company’s PathFinderTG® pancreas platform’s high negative predictive value (NPV=97%) for correctly identifying patients at very low risk of developing pancreatic cancer.
“We are extremely pleased with the results of The National Pancreatic Cyst Registry. They undoubtedly demonstrate how significant of a test PathFinderTG is for risk stratifying pancreatic cyst patients,” stated Dennis M. Smith, Jr., M.D., president and chief executive officer of RedPath Integrated Pathology.
The study aimed to evaluate the clinical validity and utility of integrated molecular pathology using PathFinderTG for differentiating patients with pancreatic cysts with low malignant potential from those with high malignant potential. The added value of integrated molecular pathology to that of traditional first-line testing is also highlighted.
“Patients with low risk PathFinderTG diagnoses had a 97% probability of follow up without malignancy. These low risk patients could be statistically differentiated from those with much higher risk of malignancy. Patients in the ‘statistically higher risk’ category have a 31-fold increased risk of cancer and those in the ‘aggressive’ category have a 76-fold increased risk of cancer,” added Dr. Smith. “Clearly, PathFinderTG plays a very valuable role in managing all cyst patients and can help clinicians make ‘surveillance versus surgery’ decisions with greater confidence.”
RedPath’s patented PathFinderTG Pancreas profile uses LOH markers, oncogene mutations, and DNA content abnormalities to stratify patients according to their risk of cancer. PathFinderTG is much better at risk-stratifying cyst patients than standard first-line tests. All patients, except those with a malignant diagnosis on cytology, are ideal candidates for testing with PathFinderTG.
About RedPath Integrated Pathology
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory.
The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers. For more information about RedPath Integrated Pathology visit www.redpathip.com or contact Andrew Mignatti at 412-224-6100.